Figure 3 | Scientific Reports

Figure 3

From: Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38+ tumors in mouse models in vivo

Figure 3

Fluorochrome-conjugated nanobodies detect CD38 on the surface of lymphoma cell lines, peripheral blood lymphocytes, and primary myeloma cells. (a) Untransfected mouse lymphoma cell lines Yac-1 and DC27.10 and their counterparts stably transfected with human CD38 (top row of panels) and human lymphoma cell lines (bottom row) were stained with Alexa647-conjugated nanobody MU1067 or an irrelevant control nanobody. (b) Blood samples from normal donors were incubated with fluorochrome-conjugated antibodies against CD45 (pan-lymphocytes), CD56 (NK cells), CD19 (B cells) and CD3 (T cells) and CD38-specific mAb LS1983-4-3, Nb JK36, or a control nanobody for 30 min at RT. Erythrocytes were lysed and cells were analyzed by flow cytometry. Gating was performed on CD45+ lymphocytes. (c) Bone marrow samples from two myeloma patients were incubated with fluorchrome-conjugated antibodies against CD45 and CD56 and nanobody MU1067 for 30 min at RT. Erythrocytes were lysed and cells were analyzed by flow cytometry. Gating was performed on lymphocytes. Myeloma cells in these patients express CD56 but do not express CD45.

Back to article page